Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | F12 | P00748 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373584 | 0.98 | PLAU (0.46) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL131316 | 0.98 | PLAU (0.46) | PLAUCYP2A6F12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL2222537 | 0.96 | PLAU (0.44) | PLAUCYP2A6F12NCF1NOS3 | |
| Ammonia Solution, Strong SCHEMBL28140044 | 0.96 | PLAU (0.44) | PLAUCYP2A6F12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL2570754 | 0.96 | PLAU (0.44) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL27879304 | 0.92 | PLAU (0.41) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL4389307 | 0.89 | LMNA (0.39) | PLAUCYP2A6F12NCF1NOS3 | |
| Quinoline SCHEMBL28833127 | 0.88 | ALDH1A1 (0.50) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL23886136 | 0.81 | PLAU (0.47) | PLAUCYP2A6F12NCF1NOS3 | |
| Bromide SCHEMBL28774149 | 0.79 | PLAU (0.42) | PLAUCYP2A6F12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 502 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115135307-A | Carrier for cell delivery | 株式会社ITO | 2022-09-30 | — | — | CN | claimed |
| US-20210093724-A1 | TOPICAL ANTI-ACNE COMPOSITION | CONCEPT MATRIX SOLUTIONS | 2021-04-01 | — | — | US | claimed |
| WO-2016010984-A2 | COMPOSITIONS AND METHODS FOR TREATING ROSACEA | TISSUE TECH, INC. (US) | 2016-01-21 | — | — | WO | claimed |
| US-20160008295-A1 | COMPOSITIONS AND METHODS FOR TREATING ROSACEA | TISSUE TECH, INC. | 2016-01-14 | — | — | US | claimed |
| US-20140154342-A1 | SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS | SANTALIS PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | US | claimed |
| EP-2736504-A1 | SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS | Santalis Pharmaceuticals Inc. (US) | 2014-06-04 | — | — | EP | claimed |
| CN-103732253-A | Use of small molecules in methods for purification of biomolecules | EMD MILLIPORE CORP | 2014-04-16 | — | — | CN | claimed |
| US-20130203969-A1 | USE OF SMALL MOLECULES IN METHODS FOR PURIFICATION OF BIOMOLECULES | EMD MILLIPORE CORPORATION (US) | 2013-08-08 | — | — | US | claimed |
| WO-2013016656-A1 | SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS | SANTALIS PHARMACEUTICALS INC. (US) | 2013-01-31 | — | — | WO | claimed |
| US-5830488-A | QUICK-DRYING; ALCOHOL, CATIONIC DISINFECTANT AND SILICONE | SHISEIDO CO., LTD. (JP) | 1998-11-03 | — | — | US | claimed |
| WO-1997000609-A1 | METHOD FOR INCREASING THE EFFICACY OF AN ODOR MASKING AGENT | HENKEL CORPORATION (US) | 1997-01-09 | — | — | WO | claimed |
| US-5089252-A | Amphoteric polymer of betainised dialkylaminoalkyl acrylate or dialkylaminoalkyl acrylamide and cationic deriative | L'OREAL (FR) | 1992-02-18 | — | — | US | claimed |
| JP-56030902-A | — | — | None | — | — | JP | disclosed |
| CN-118159133-A | Permanent disinfection composition and method for permanent disinfection | 法国特种经营公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024092394-A1 | ANTIMICROBIAL FOAM HAND SOAP COMPOSITIONS WITH COLOR INDICATOR SYSTEMS | ECOLAB USA INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024085105-A1 | ANTI-INFLAMMATORY AGENT, TNF-α PRODUCTION INHIBITOR, INTERLEUKIN-10 PRODUCTION PROMOTOR, SKIN EXTERNAL APPLICATION COMPOSITION, FOOD OR BEVERAGE COMPOSITION, METHOD FOR PREVENTING, AMELIORATING, OR TREATING INFLAMMATORY DISEASES, AND USE OF PLANT-DERIVED POLYAMINE-CONTAINING EXTRACT FOR MANUFACTURING ANTI-INFLAMMATORY AGENT | 東洋紡株式会社 | 2024-04-25 | — | — | WO | disclosed |
| US-4051234-A | BIS-GUANIDINE COMPOUND, ETHYLENEDIAMINEDIACETIC ACID OR SALT AS CHELATOR | THE PROCTER & GAMBLE COMPANY (US) | 1977-09-27 | — | — | US | disclosed |
| US-4025616-A | Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies | THE PROCTER & GAMBLE COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
| US-3937807-A | BISBIGUANIDE COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1976-02-10 | — | — | US | disclosed |
| US-3934002-A | BIS-GUANIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093724-A1 | TOPICAL ANTI-ACNE COMPOSITION | CUTA, EBP, CNR2 | ACHE 3814/4885PLAU 3512/4885CYP2A6 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.